ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.820,57
-0,39%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) News

STRO

Sutro Biopharma (STRO)

Sutro Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:STRO
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202423h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:STROSutro Biopharma Inc
13/05/202422h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
13/05/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
13/05/202422h30GlobeNewswire Inc.Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
30/04/202414h00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialNASDAQ:STROSutro Biopharma Inc
02/04/202412h18GlobeNewswire Inc.Sutro Biopharma Announces Pricing of $75 Million Underwritten OfferingNASDAQ:STROSutro Biopharma Inc
25/03/202421h30GlobeNewswire Inc.Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
07/03/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
05/03/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
05/03/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
04/03/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
27/02/202422h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:STROSutro Biopharma Inc
13/02/202418h16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STROSutro Biopharma Inc
12/02/202412h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STROSutro Biopharma Inc
09/02/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
09/02/202422h25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:STROSutro Biopharma Inc
06/02/202422h05GlobeNewswire Inc.Sutro Biopharma to Participate in Upcoming Investor ConferencesNASDAQ:STROSutro Biopharma Inc
31/01/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
29/01/202423h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STROSutro Biopharma Inc
08/01/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
04/01/202422h05GlobeNewswire Inc.Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCNASDAQ:STROSutro Biopharma Inc
14/12/202322h05GlobeNewswire Inc.Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024NASDAQ:STROSutro Biopharma Inc
11/12/202322h05GlobeNewswire Inc.Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023NASDAQ:STROSutro Biopharma Inc
04/12/202322h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
04/12/202322h05GlobeNewswire Inc.Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:STROSutro Biopharma Inc
27/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
27/11/202322h00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:STROSutro Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:STRO

Kürzlich von Ihnen besucht

COIN
SILV2USD
Escrowed Illuvium 2
ASX
GRMDA
LSE
51JG
Net.r.i. 1.003%
BOV
DEOP34
Diageo
LSE
0HBV
Ubs Etf Msci Switzerland...
LSE
0J2L
Electroaparataj
USOTC
RCTY
Rocket City Enterprises (CE)
ASX
ILFDA
LSE
IQCY
Amundi Smart
GATE
TEDUSDT
Tezos Domains
LSE
0ACD
Vanguard Global Aggregat...
BIT
F12540
Vontobel Financial Produ...
COIN
GOLDLGBP
GOLD
TG
LFIN
Lyxor STOXX Europe 600 F...
ASX
MOTN
HUOB
MCONTENTUSDT
MContent
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten